A bone graft composition promoting osteogenic capacity is provided. The bone graft composition includes an osteoinductive component including statins and a biodegradable polymer and an osteoconductive matrix including a biodegradable calcium phosphate ceramic, wherein the amount of the calcium phosphate ceramic is about 70 to 95 wt % based on the total weight of the bone graft composition. The bone graft composition can achieve the optimal release control characteristics of the statins in the osteoinductive component.

The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided.

A method of treating vascular disease in a patient is disclosed that comprises deploying a bioabsorbable polymer scaffold composed of a plurality of struts at a stenotic segment of an artery of a patient, wherein after the scaffold supports the segment at an increased diameter for a period of time the polymer degrades and is progressively replaced by de novo formation of malleable provisional matrix comprising proteoglycan, wherein as the scaffold becomes more malleable and becomes disconnected as it degrades, wherein following coverage of the struts by a neointima layer and loss of mechanical support provided by the scaffold, the scaffold is pulled outward by positive remodeling of the vessel wall of the scaffolded segment.

A multilayer protein film has a mass of greater than 0.5 g/cm.sup.2 and consists essentially of protein. A drug delivery device comprises the multilayer protein film onto which a pharmaceutically active agent can be loaded. A biomedical implant comprises an implant substrate and the multilayer protein film on at least a portion of the implant substrate surface. A method of making a multilayer protein film having a mass of greater than 0.5 g/cm.sup.2 comprises contacting a substrate with a protein solution at a temperature of from about 30 C. to about 95 C, wherein a multilayer protein film having a mass of greater than 0.5 g/cm.sup.2 is formed on the substrate.

The present document is directed to a titanium dioxide scaffold comprising a hydrogel coating comprising a biologically active substance. Also disclosed is a method for producing a thin hydrogel coating on a titanium dioxide scaffold and uses of the hydrogel coated scaffolds as medical implants.

The invention relates to a method for healing blood vessels by stimulating the formation of a confluent endothelial autologous cell layer in vivo on an implantable metallic stent having a lumen and a luminal surface, and an exterior surface. More specifically, the method includes implanting the stent with a coating in a patient in need of thereof; wherein the coating includes one or more layers of a matrix covalently adherent on said luminal and exterior surface of said stent containing one or more pharmaceutical substances on said exterior surface and a therapeutically effective amount of a single type of antibody, antibody fragments or combinations thereof being compatible to binding selectively to a specific cell surface antigen of circulating autologous endothelial progenitor cells in peripheral blood. In addition, genetically engineered endothelial progenitor cells can be captured on said luminal surface of stent in vivo, to proliferate to form rapidly a confluent endothelium in situ.